BioNap Consulting’s Jason Napodano Issues an Update on BriaCell Therapeutics Corp.

Berkeley, CA and Vancouver, BC–(Marketwired – September 27, 2016) – BioNap Consulting, Inc.’s Senior Equity Analyst, Jason Napodano, CFA, issued an update outlining the meaningful progress of BriaCell Therapeutics Corp. (TSX VENTURE: BCT) (OTCQB: BCTXF) or BriaCell towards initiation of Phase I/IIa clinical testing of BriaVax™, BriaCell’s proprietary allogeneic whole tumor cell vaccine, in late-stage breast cancer patients in the fourth quarter of 2016.

BriaCell is currently completing the final stages of the manufacturing of the vaccine for the clinical study. The company expects to initiate a Phase I/IIa program with BriaVax™ in the fourth quarter of 2016. The trial is expected to enroll up to 24 late-stage breast cancer patients.

The company recently appointed Dr. Jarrod P. Holmes, a Board Certified Oncologist and a leading expert in breast cancer vaccines at Annadel Medical Group and St. Joseph Health-Sonoma County in Santa Rosa, CA, as a Principal Investigator (PI) for the upcoming Phase I/IIa clinical trials. Dr. Holmes will be working closely with Cancer Insight, LLC, a leading cancer-vaccine focused clinical research organization (CRO) – contacted by BriaCell, to manage the clinical and regulatory aspects of the Phase I/IIa studies.

BriaCell has secured sufficient amounts of cash for the operations, clinical trials, and the companion diagnostic platform development, known as BriaDx™, in the near-term. The company has completed a series of brokered and non-brokered financings in 2016. Most recently, BriaCell completed the closing of a non-brokered private placement financing, generating gross proceeds of $1.7 million.

The company recently appointed NY-based RK Equity Advisors, LLC and TrueNorth Lifesciences, LLC for corporate advisory services. Pursuant to the Agreement, RK Equity and TruthNorth will assist BriaCell in engaging select members of the international investment community with a focus on increasing awareness of BriaCell and its unique growth strategy, as well as assisting with the commercialization of its product and other market opportunities.

Jason Napodano concluded that the upcoming initiation of the Phase I/IIa clinical trial, and the higher awareness of the company within the investment community will present a meaningful catalyst for BriaCell share price in the near-term. For the full article, please see

About BioNap, Inc.

BioNap Consulting, Inc. (BioNap™) is an investor intelligence and strategic advisory firm that produces high-quality market research on companies in the pharmaceutical, biotechnology, and medical device sector. The company works directly with both investors and biopharma companies in an effort to achieve the common goal of maximizing investment in the healthcare sector.

Before starting his own firm in July 2015, Jason Napodano, CFA has served as Equity Research Analyst at Zacks Investment Research for over 12 years writing highly detailed small-cap biotechnology research reports. Currently, as Owner and Senior Equity Analyst at BioNap Consulting, Napodano continues to analyze and perform due diligence on a large number of biotechnology companies.

For more information on BrioNap, Inc., please see

About BriaCell

BriaCell is an immuno-oncology biotechnology company developing a more targeted, less toxic approach to cancer management. BriaCell’s mission is to serve late-stage cancer patients with no other treatment options.

Immunotherapy has come to the forefront of the fight against cancer, harnessing the body’s own immune system in recognizing and selectively destroying the cancer cells while sparing normal ones. Immunotherapy, in addition to generally being more targeted and less toxic than commonly used types of chemotherapy, is also thought to be a strong type of approach aimed at preventing cancer recurrence.

BriaVax™, the Company’s lead product, is a genetically engineered whole-cell vaccine derived from a human breast tumor cell line. This targeted vaccine is believed to generate strong antibody and T-cell responses, which in turn may boost the immune system to recognize and eliminate cancerous cells. The Company has already demonstrated encouraging clinical results, and is intent on building upon these results to further advance BriaVax™ through additional FDA-approved clinical trials in order to help cancer patients with no other options. The results of two previous FDA Phase I clinical trials have been encouraging in terms of both safety and efficacy in patients with advanced solid tumors (17 breast cancer, 1 ovarian cancer).

In some cases, patient survival was three to five times longer than would have been expected. For more information, please visit

Contact Information

For further information contact:

BriaCell Therapeutics Corp.
820 Heinz Avenue
Berkeley, CA 94710
Ms. Farrah Dean
Manager, Corporate Development
Phone: 1-888-485-6340
Email: [email protected]

The TSX Venture Exchange Inc. has in no way passed upon the merits of the Company and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward-Looking Information

Except for the statements of historical fact, this news release contains “forward-looking information” within the meaning of the applicable Canadian securities legislation which involves known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company’s public filings available at

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Skip to content